Review: In alcohol use disorders, oral naltrexone, 50 mg/d, or acamprosate reduces return to drinking

Annals of Internal Medicine

Volumn 161, Issue 8, 2014, Pages JC7-

  Jonas, D E ^a   Kraemer, Kevin L ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; DISULFIRAM; NALTREXONE; RIBOFLAVIN;

ADULT; ALCOHOL USE DISORDER; ATTRIBUTABLE RISK; COHORT ANALYSIS; DIARRHEA; DIZZINESS; HUMAN; META ANALYSIS; META ANALYSIS (TOPIC); NAUSEA; NOTE; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; OUTPATIENT; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; SYSTEMATIC REVIEW (TOPIC); VOMITING; ALCOHOL-RELATED DISORDERS;

ALCOHOL-RELATED DISORDERS; HUMANS;

EID: 84924924201     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-161-8-201410210-02007     Document Type: Note

References (4)

1. Institute of Medicine Committee on Crossing the Quality Chasm: Adaptation to Mental Health and Addictive Disorders.Washington, DC: National Academies Press; 2006.
2. Rösner S, Hackl-Herrwerth A, Leucht S, et al. Cochrane Database Syst Rev. 2010;(12): CD001867.
3. Rösner S, Hackl-Herrwerth A, Leucht S, et al. Cochrane Database Syst Rev. 2010;(9): CD004332.
4. Bradley KA, Kivlahan DR. JAMA. 2014;311: 1861-2.